

## **BIBLIOGRAFÍA**



---

## 7. BIBLIOGRAFÍA

Alcorta, D. A., Xiong, Y., Phelps, D., Hannon, G., Beach, D., and Barrett, J. C. (1996). Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. *Proc Natl Acad Sci U S A* 93, 13742-13747.

Andreassen, P. R., Lacroix, F. B., Lohez, O. D., and Margolis, R. L. (2001). Neither p21<sup>WAF1</sup> nor 14-3-3sigma prevents G2 progression to mitotic catastrophe in human colon carcinoma cells after DNA damage, but p21WAF1 induces stable G1 arrest in resulting tetraploid cells. *Cancer Res* 61, 7660-7668.

Asai, G., Yamamoto, N., Toi, M., Shin, E., Nishiyama, K., Sekine, T., Nomura, Y., Takashima, S., Kimura, M., and Tominaga, T. (2002). Pharmacokinetic and pharmacodynamic study of IST-622, a novel synthetic derivative of chartreusin, by oral administration in a phase II study of patients with breast cancer. *Cancer Chemother Pharmacol* 49, 468-472.

Baek, K. H., Shin, H. J., Yoo, J. K., Cho, J. H., Choi, Y. H., Sung, Y. C., McKeon, F., and Lee, C. W. (2003). p53 deficiency and defective mitotic checkpoint in proliferating T lymphocytes increase chromosomal instability through aberrant exit from mitotic arrest. *J Leukoc Biol* 73, 850-861.

Barbisan, L. F., Mello, M. L., Russo, J., and Vidal, B. C. (1999). Apoptosis and catastrophic cell death in benzo[a]pyrene-transformed human breast epithelial cells. *Mutat Res* 431, 133-139.

Barboule, N., Chadebecq, P., Baldin, V., Vidal, S., and Valette, A. (1997). Involvement of p21 in mitotic exit after paclitaxel treatment in MCF-7 breast adenocarcinoma cell line. *Oncogene* 15, 2867-2875.

Barceló, F., Pons, J., Petitpierre, E., Barjau, I., and Portugal, J. (1997). Polymorphic curvature of satellite DNA in three subspecies of the beetle *Pimelia sparsa*. *Eur J Biochem* 244, 318-324.

Baus, F., Gire, V., Fisher, D., Piette, J., and Dulic, V. (2003). Permanent cell cycle exit in G2 phase after DNA damage in normal human fibroblasts. *Embo J* 22, 3992-4002.

Beato, M. (1990). Course on DNA-Protein Interaction (Madrid, Spain, Fundación Juan March -Serie Universitaria-).

Beausejour, C. M., Krtolica, A., Galimi, F., Narita, M., Lowe, S. W., Yaswen, P., and Campisi, J. (2003). Reversal of human cellular senescence: roles of the p53 and p16 pathways. *EMBO J* 22, 4212-4222.

Bein, K., Odell-Fiddler, E. T., and Drinane, M. (2004). Role of TGF- $\beta$ 1 and JNK signaling in capillary tube patterning. *Am J Physiol Cell Physiol* 287, C1012-C1022.

- 
- Belloc, F., Lacombe, F., Dumain, P., Lopez, F., Bernard, P., Boisseau, M. R., and Reifers, J. (1992). Intercalation of anthracyclines into living cell DNA analyzed by flow cytometry. *Cytometry* 13, 880-885.
- Bellorini, M., Moncollin, V., D'Incalci, M., Mongelli, N., and Mantovani, R. (1995). Distamycin A and tallimustine inhibit TBP binding and basal in vitro transcription. *Nucleic Acids Res* 23, 1657-1663.
- Bernards, R., Schackleford, G. M., Gerber, M. R., Horowitz, J. M., Friend, S. H., Schartl, M., Bogenmann, E., Rapaport, J. M., McGee, T., Dryja, T. P., and et al. (1989). Structure and expression of the murine retinoblastoma gene and characterization of its encoded protein. *Proc Natl Acad Sci U S A* 86, 6474-6478.
- Bernstein, C., Bernstein, H., Payne, C. M., and Garewal, H. (2002). DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. *Mutat Res* 511, 145-178.
- Black, A. R., Black, J. D., and Azizkhan-Clifford, J. (2001). Sp1 and kruppel-like factor family of transcription factors in cell growth regulation and cancer. *J Cell Physiol* 188, 143-160.
- Black, A. R., Jensen, D., Lin, S. Y., and Azizkhan, J. C. (1999). Growth/Cell cycle regulation of Sp1 phosphorylation. *J Biol Chem* 274, 1207-1215.
- Bladier, C., Wolvetang, E. J., Hutchinson, P., de Haan, J. B., and Kola, I. (1997). Response of a primary human fibroblast cell line to H<sub>2</sub>O<sub>2</sub>: senescence-like growth arrest or apoptosis? *Cell Growth Differ* 8, 589-598.
- Boatright, K. M., Salvesen, G.S. (2003). Mechanisms of caspase activation. *Curr Opin Cell Biol* 15, 725-731.
- Booser, D. J., and Hortobagyi, G. N. (1994). Anthracycline antibiotics in cancer therapy. Focus on drug resistance. *Drugs* 47, 223-258.
- Botella, L. M., Sánchez-Elsner, T., Rius, C., Corbi, A., and Bernabéu, C. (2001). Identification of a critical Sp1 site within the endoglin promoter and its involvement in the transforming growth factor- $\beta$  stimulation. *J Biol Chem* 276, 34486-34494.
- Boxer, L. M., and Dang, C. V. (2001). Translocations involving c-myc and c-myc function. *Oncogene* 20, 5595-5610.
- Bradford, M. M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* 72, 248-254.
- Bree, R. T., Stenson-Cox, C., Grealy, M., Byrnes, L., Gorman, A. M., and Samali, A. (2002). Cellular longevity: role of apoptosis and replicative senescence. *Biogerontology* 3, 195-206.

- 
- Briggs, M. R., Kadonaga, J. T., Bell, S. P., and Tjian, R. (1986). Purification and biochemical characterization of the promoter-specific transcription factor, Sp1. *Science* 234, 47-52.
- Broggini, M., Ponti, M., Ottolenghi, S., D'Incalci, M., Mongelli, N., and Mantovani, R. (1989). Distamycins inhibit the binding of OTF-1 and NFE-1 transactors to their conserved DNA elements. *Nucleic Acids Res* 17, 1051-1059.
- Brown JM, A. L. (2005). The role of apoptosis in cancer development and treatment response. *Nat Rev Cancer* 5, 231-237.
- Brown, J. M., and Attardi, L. D. (2005). The role of apoptosis in cancer development and treatment response. *Nat Rev Cancer* 5, 231-237.
- Brown, J. M., and Wouters, B. G. (1999). Apoptosis, p53, and tumor cell sensitivity to anticancer agents. *Cancer Res* 59, 1391-1399.
- Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., and Vogelstein, B. (1998). Requirement for p53 and p21 to sustain G<sub>2</sub> arrest after DNA damage. *Science* 282, 1497-1501.
- Burlacu, A. (2003). Regulation of apoptosis by Bcl-2 family proteins. *J Cell Mol Med* 7, 249-257.
- Castedo, M., Perfettini, J. L., Roumier, T., Andreau, K., Medema, R., and Kroemer, G. (2004a). Cell death by mitotic catastrophe: a molecular definition. *Oncogene* 23, 2825-2837.
- Castedo, M., Perfettini, J. L., Roumier, T., Valent, A., Raslova, H., Yakushijin, K., Horne, D., Feunteun, J., Lenoir, G., Medema, R., *et al.* (2004b). Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy. *Oncogene* 23, 4362-4370.
- Chabner, B. A., and Longo, D. L. (2001). *Cancer Chemotherapy and Biotherapy: Principles and Practice*, 3rd edn (Philadelphia, PA, Lippincott-Williams & Wilkins).
- Chaires, J. B. (1990). Biophysical chemistry of the daunomycin-DNA interaction. *Biophys Chem* 35, 191-202.
- Chaires, J. B. (1996). Molecular recognition of DNA by daunorubicin. In *Advances in DNA sequence specific agents*, L. Hurley, and J. B. Chaires, eds. (Greenwich, CT, JAI Press Inc.), pp. 141-167.
- Chaires, J. B. (1998). Drug-DNA interactions. *Curr Opin Struct Biol* 8, 314-320.
- Chaires, J. B., Fox, K. R., Herrera, J. E., Britt, M., and Waring, M. J. (1987). Site and sequence specificity of the daunomycin-DNA interaction. *Biochemistry* 26, 8227-8236.

Chaires, J. B., Herrera, J. E., and Waring, M. J. (1990). Preferential binding of daunomycin to 5'ATCG and 5'ATGC sequences revealed by footprinting titration experiments. *Biochemistry* 29, 6145-6153.

Chaires, J. B., Leng, F. F., Przewloka, T., Fokt, I., Ling, Y. H., Perez-Soler, R., and Priebe, W. (1997). Structure-based design of a new bisintercalating anthracycline antibiotic. *J Med Chem* 40, 261-266.

Chan, T. A., Hermeking, H., Lengauer, C., Kinzler, K. W., and Vogelstein, B. (1999). 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. *Nature* 401, 616-620.

Chang, B. D., Broude, E. V., Dokmanovic, M., Zhu, H., Ruth, A., Xuan, Y., Kandel, E. S., Lausch, E., Christov, K., and Roninson, I. B. (1999a). A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. *Cancer Res* 59, 3761-3767.

Chang, B. D., Swift, M. E., Shen, M., Fang, J., Broude, E. V., and Roninson, I. B. (2002). Molecular determinants of terminal growth arrest induced in tumor cells by a chemotherapeutic agent. *Proc Natl Acad Sci USA* 99, 389-394.

Chang, B. D., Xuan, Y., Broude, E. V., Zhu, H., Schott, B., Fang, J., and Roninson, I. B. (1999b). Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. *Oncogene* 18, 4808-4818.

Chaturvedi, V., Qin, J. Z., Stennett, L., Choubey, D., and Nickoloff, B. J. (2004). Resistance to UV-induced apoptosis in human keratinocytes during accelerated senescence is associated with functional inactivation of p53. *J Cell Physiol* 198, 100-109.

Chen, Q. M., Liu, J., and Merrett, J. B. (2000). Apoptosis or senescence-like growth arrest: influence of cell-cycle position, p53, p21 and bax in H<sub>2</sub>O<sub>2</sub> response of normal human fibroblasts. *Biochem J* 347, 543-551.

Chen, X., Ko, L. J., Jayaraman, L., and Prives, C. (1996). p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. *Genes Dev* 10, 2438-2451.

Chiang, S.-Y., Azizkhan, J. C., and Beerman, T. A. (1998). A comparison of DNA-binding drugs as inhibitors of E2F1- and Sp1-DNA complexes and associated gene expression. *Biochemistry* 37, 3109-3115.

Collado, M., Medema, R. H., Garcia-Cao, I., Dubuisson, M. L., Barradas, M., Glassford, J., Rivas, C., Burgering, B. M., Serrano, M., and Lam, E. W. (2000). Inhibition of the phosphoinositide 3-kinase pathway induces a senescence-like arrest mediated by p27<sup>Kip1</sup>. *J Biol Chem* 275, 21960-21968.

Collins, K., Jacks, T., and Pavletich, N. P. (1997). The cell cycle and cancer. *Proc Natl Acad Sci U S A* 94, 2776-2778.

- Coqueret, O. (2002). Linking cyclins to transcriptional control. *Gene* 299, 35-55.
- Craig, C., Kim, M., Ohri, E., Wersto, R., Katayose, D., Li, Z., Choi, Y. H., Mudahar, B., Srivastava, S., Seth, P., and Cowan, K. (1998). Effects of adenovirus-mediated p16INK4A expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cells. *Oncogene* 16, 265-272.
- da Silva, C. P., de Oliveira, C. R., da Conceição, M., and de Lima, P. (1996). Apoptosis as a mechanism of cell death induced by different chemotherapeutic drugs in human leukemic T-lymphocytes. *Biochem Pharmacol* 51, 1331-1340.
- D'Assoro, A. B., Busby, R., Suino, K., Delva, E., Almodovar-Mercado, G. J., Johnson, H., Folk, C., Farrugia, D. J., Vasile, V., Stivala, F., and Salisbury, J. L. (2004). Genotoxic stress leads to centrosome amplification in breast cancer cell lines that have an inactive G1/S cell cycle checkpoint. *Oncogene* 23, 4068-4075.
- Desbarats, L., Schneider, A., Muller, D., Burgin, A., and Eilers, M. (1996). Myc: A single gene controls both proliferation and apoptosis in mammalian cells. *Experientia* 52, 1123-1129.
- Dickinson, L. A., Gulizia, R. J., Trauger, J. W., Baird, E. E., Mosier, D. E., Gottesfeld, J. M., and Dervan, P. B. (1998). Inhibition of RNA polymerase II transcription in human cells by synthetic DNA-binding ligands. *Proc Natl Acad Sci USA* 95, 12890-12895.
- Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., Pereira-Smith, O., *et al.* (1995). A biomarker that identifies senescent human cells in culture and in aging skin in vivo. *Proc Natl Acad Sci USA* 92, 9363-9367.
- Donehower, L. A. (2002). Does p53 affect organismal aging? *J Cell Physiol* 192, 23-33.
- Doyle, A., Griffiths, J. B., and Newell, D. G. (1995). *Cell & Tissue Culture: Laboratory procedures* (New York, John Wiley & sons).
- el-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., and Vogelstein, B. (1992). Definition of a consensus binding site for p53. *Nat Genet* 1, 45-49.
- Elliott, M. J., Murphy, K. M., Stribinskiene, L., Ranganathan, V., Sturges, E., Farnsworth, M. L., and Lock, R. B. (1999). Bcl-2 inhibits early apoptotic events and reveals post-mitotic multinucleation without affecting cell cycle arrest in human epithelial tumor cells exposed to etoposide. *Cancer Chemother Pharmacol* 44, 1-11.
- Enoch, T., and Norbury, C. (1995). Cellular responses to DNA damage: cell-cycle checkpoints, apoptosis and the roles of p53 and ATM. *Trends Biochem Sci* 20, 426-430.
- Erenpreisa, J., Cragg, M. S., Ivanov, A., Cragg, M., Selivanova, G., and Illidge, T. (2001). Mitotic death: a mechanism of survival? A review. *Cancer Cell Int* 1, 1.

- Essmann, F., Engels, I. H., Totzke, G., Schulze-Osthoff, K., and Janicke, R. U. (2004). Apoptosis resistance of MCF-7 breast carcinoma cells to ionizing radiation is independent of p53 and cell cycle control but caused by the lack of caspase-3 and a caffeine-inhibitable event. *Cancer Res* 64, 7065-7072.
- Fandos, C., Sánchez-Feutrie, M., Santalucía, T., Viñals, F., Cadefau, J., Gumà, A., Cussó, R., Kaliman, P., Canicio, J., Palacín, M., and Zorzano, A. (1999). GLUT1 glucose transporter gene transcription is repressed by Sp3. Evidence for a regulatory role of Sp3 during myogenesis. *J Mol Biol* 294, 103-119.
- Ferbeyre, G., de Stanchina, E., Lin, A. W., Querido, E., McCurrach, M. E., Hannon, G. J., and Lowe, S. W. (2002). Oncogenic ras and p53 cooperate to induce cellular senescence. *Mol Cell Biol* 22, 3497-3508.
- Ferbeyre, G., de Stanchina, E., Querido, E., Baptiste, N., Prives, C., and Lowe, S. W. (2000). PML is induced by oncogenic *ras* and promotes premature senescence. *Genes Dev* 14, 2015-2027.
- Fox, K. R., Webster, R., Phelps, R. J., Fokt, I., and Priebe, W. (2004). Sequence selective binding of bis-daunorubicin WP631 to DNA. *Eur J Biochem* 271, 3556-3566.
- Gaidarova, S., and Jiménez, S. A. (2002). Inhibition of basal and transforming growth factor- $\beta$ -induced stimulation of COL1A1 transcription by the DNA intercalators, mitoxantrone and WP631, in cultured human dermal fibroblasts. *J Biol Chem* 277, 38737-38745.
- Garnier-Suillerot, A., Marbeuf-Gueye, C., Salerno, M., Loetchutinat, C., Fokt, I., Krawczyk, M., Kowalczyk, T., and Priebe, W. (2001). Analysis of drug transport kinetics in multidrug-resistant cells: implications for drug action. *Curr Med Chem* 8, 51-64.
- Gartel, A. L., and Shchors, K. (2003). Mechanisms of c-myc-mediated transcriptional repression of growth arrest genes. *Exp Cell Res* 283, 17-21.
- Gartel, A. L., Ye, X., Goufman, E., Shianov, P., Hay, N., Najmabadi, F., and Tyner, A. L. (2001). Myc represses the p21<sup>(WAF1/CIP1)</sup> promoter and interacts with Sp1/Sp3. *Proc Natl Acad Sci USA* 98, 4510-4515.
- Gewirtz, D. A. (1999). A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. *Biochem Pharmacol* 57, 727-741.
- Gewirtz, D. A., Sundaram, S., and Magnet, K. J. (2000). Influence of topoisomerase II inhibitors and ionizing radiation on growth arrest and cell death pathways in the breast tumor cell. *Cell Biochem Biophys* 33, 19-31.
- Gottesfeld, J. M., Turner, J. M., and Dervan, P. B. (2000). Chemical approaches to control gene expression. *Gene Expr* 9, 77-91.



- 
- Grinstein, E., Jundt, F., Weinert, I., Wernet, P., and Royer, H. D. (2002). Sp1 as G1 cell cycle phase specific transcription factor in epithelial cells. *Oncogene* *21*, 1485-1492.
- Guigo, R. (1997). Computational gene identification: an open problem. *Comput Chem* *21*, 215-222.
- Hagen, G., Muller, S., Beato, M., and Suske, G. (1994). Sp1-mediated transcriptional activation is repressed by Sp3. *EMBO J* *13*, 3843-3851.
- Hanahan, D. (1983). Studies on transformation of *Escherichia coli* with plasmids. *J Mol Biol* *166*, 557-580.
- Hay, N., Bishop, M., and Levens, D. (1987). Regulatory elements that modulate expression of human c-myc. *Genes Devel* *1*, 659-671.
- Holmes, D. S., Quigley, M. (1981). A rapid boiling method for the preparation of bacterial plasmids. *Anal Biochem* *114*, 193-197.
- Horowitz, A. T., Barenholz, Y., and Gabizon, A. A. (1992). *In vitro* cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release. *Biochim Biophys Acta* *1109*, 203-209.
- Hosokawa, M. (2002). A higher oxidative status accelerates senescence and aggravates age-dependent disorders in SAMP strains of mice. *Mech Ageing Dev* *123*, 1553-1561.
- Hu, G. G., Shui, X., Leng, F., Priebe, W., Chaires, J. B., and Williams, L. D. (1997). Structure of a DNA-bisdaunomycin complex. *Biochemistry* *36*, 5940-5946.
- Huang, X., Tran, T., Zhang, L., Hatcher, R., and Zhang, P. (2005). DNA damage-induced mitotic catastrophe is mediated by the Chk1-dependent mitotic exit DNA damage checkpoint. *Proc Natl Acad Sci U S A* *102*, 1065-1070.
- Inge, T. H., Casson, L. K., Priebe, W., Trent, J. O., Georgeson, K. E., Miller, D. M., and Bates, P. J. (2002). Importance of Sp1 consensus motifs in the MYCN promoter. *Surgery* *132*, 232-238.
- Inge, T. H., Harris, N. L., Wu, J., Azizkhan, R. G., and Priebe, W. (2004). WP744 is a novel anthracycline with enhanced activity against neuroblastoma. *J Surg Res* *121*, 187-196.
- Kadonaga, J. T., Carner, K. R., Masiarz, F. R., and Tjian, R. (1987). Isolation of cDNA encoding transcription factor Sp1 and functional analysis of the DNA binding domain. *Cell* *51*, 1079-1090.
- Kardassis, D., Papakosta, P., Pardali, K., and Moustakas, A. (1999). c-Jun transactivates the promoter of the human p21(WAF1/Cip1) gene by acting as a superactivator of the ubiquitous transcription factor Sp1. *J Biol Chem* *274*, 29572-29581.
- Kopka, M. L., Han, G. W., Goodsell, D. S., Chiu, T. K., Walker, W. L., Lown, J. W., and Dickerson, R. E. (1998). DNA sequence recognition in the minor groove by

polyamides, using a GC-specific reading element: A perspective from crystallography. In *Structure, Motion, Interaction and Expression of Biological Macromolecules*, R. H. Sarma, and M. H. Sarma, eds. (Albany, NY, Adenine Press), pp. 177-191.

Koutsodontis, G., Moustakas, A., and Kardassis, D. (2002). The role of Sp1 family members, the proximal GC-rich motifs, and the upstream enhancer region in the regulation of the human cell cycle inhibitor p21(WAF-1/Cip1) gene promoter. *Biochemistry* 41, 12771-12784.

Kurz, D. J., Decary, S., Hong, Y., and Erusalimsky, J. D. (2000). Senescence-associated  $\beta$ -galactosidase reflects an increase in lysosomal mass during replicative ageing of human endothelial cells. *J Cell Sci* 113, 3613-3622.

Laemmli, U. K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* 227, 680-685.

Lampidis, T. J., Kolonias, D., Podona, T., Israel, M., Safa, A. R., Lothstein, L., Savaraj, N., Tapiero, H., and Priebe, W. (1997). Circumvention of P-GP MDR as a function of anthracycline lipophilicity and charge. *Biochemistry* 36, 2679-2685.

Lawrence, D. S., Copper, J. E., and Smith, C. D. (2001). Structure-activity studies of substituted quinoxalinones as multiple-drug-resistance antagonists. *J Med Chem* 44, 594-601.

Lee, B. D., Li, Z., French, K. J., Zhuang, Y., Xia, Z., Smith, C. D., Zhang, Y., and Berger, S. A. (2004). Synthesis and evaluation of dihydropyrroloquinolines that selectively antagonize P-glycoprotein. *J Med Chem* 47, 1413-1422.

Leng, F. (1997) Interaction of daunorubicin and its derivatives with DNA, Ph.D. Thesis, University of Mississippi Medical Center, Jackson MS.

Leng, F., Priebe, W., and Chaires, J. B. (1998). Ultratight DNA binding of a new bisintercalating anthracycline antibiotic. *Biochemistry* 37, 1743-1753.

Ling, Y. H., Priebe, W., and Perez-Soler, R. (1993). Apoptosis induced by anthracycline antibiotics in P388 parent and multidrug-resistant cells. *Cancer Res* 53, 1845-1852.

Lock, R. B., and Stribinskiene, L. (1996). Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival. *Cancer Res* 56, 4006-4012.

Lodish, H., Berk, A., Zipursky, L. S., Matsudaira, P., Baltimore, D. & Darnell, J. (2000). *Molecular Cell Biology*, 4th edn (W. H. Freeman).

Lowe, S. W., Ruley, H. E., Jacks, T., and Housman, D. E. (1993). p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. *Cell* 74, 957-967.

MacKenzie, K. L., Franco, S., May, C., Sadelain, M., and Moore, M. A. (2000). Mass cultured human fibroblasts overexpressing hTERT encounter a growth crisis following an extended period of proliferation. *Exp Cell Res* 259, 336-350.

- Majello, B., De Luca, P., Hagen, G., Suske, G., and Lania, L. (1994). Different members of the Sp1 multigene family exert opposite transcriptional regulation of the long terminal repeat of HIV-1. *Nucleic Acids Res* 22, 4914-4921.
- Mansilla, S., Piña, B., and Portugal, J. (2003). Daunorubicin-induced variations in gene transcription: commitment to proliferation arrest, senescence and apoptosis. *Biochem J* 372, 703-711.
- Mansilla, S., and Portugal, J. (2002). Occurrence of DNA sequences specifically recognized by drugs in human promoters. *J Biomol Struct Dyn* 19, 669-679.
- Mansilla, S., Priebe, W., and Portugal, J. (2004). Sp1-targeted inhibition of gene transcription by WP631 in transfected lymphocytes. *Biochemistry* 43, 7584-7592.
- Marco, E., García-Nieto, R., and Gago, F. (2003). Assessment by molecular dynamics simulations of the structural determinants of DNA-binding specificity for transcription factor Sp1. *J Mol Biol* 328, 9-32.
- Marín, S., Mansilla, S., Garcia-Reyero, N., Rojas, M., Portugal, J., and Piña, B. (2002). Promoter-specific inhibition of transcription by daunorubicin in *Saccharomyces cerevisiae*. *Biochem J* 368, 131-136.
- Martín, B., Vaquero, A., Priebe, W., and Portugal, J. (1999). Bisanthracycline WP631 inhibits basal and Sp1-activated transcription initiation *in vitro*. *Nucleic Acids Res* 27, 3402-3409.
- Matsumoto, Y., Miyake, K., Kunishio, K., Tamiya, T., and Seigo, N. (2004). Reduction of expression of the multidrug resistance protein (MRP)1 in glioma cells by antisense phosphorothioate oligonucleotides. *J Med Invest* 51, 194-201.
- Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., and Gianni, L. (2004). Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. *Pharmacol Rev* 56, 185-229.
- Miracco, C., Maellaro, E., Pacenti, L., Del Bello, B., Valentini, M. A., Rubegni, P., Pirtoli, L., Volpi, C., Santopietro, R., and Tosi, P. (2003). Evaluation of MDR1, LRP, MRP, and topoisomerase IIalpha gene mRNA transcripts before and after interferon-alpha, and correlation with the mRNA expression level of the telomerase subunits hTERT and TEP1 in five unselected human melanoma cell lines. *Int J Oncol* 23, 213-220.
- Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *J Immunol Methods* 65, 55-63.
- Muredda, M., Nunoya, K., Burtch-Wright, R. A., Kurz, E. U., Cole, S. P., Deeley, R. G., Zhang, D. W., Gu, H. M., and Vasa, M. (2003). Cloning and characterization of the murine and rat *mrp1* promoter regions. Characterization of the role of polar amino acid residues within predicted transmembrane helix 17 in determining the substrate specificity of multidrug resistance protein 3. *Mol Pharmacol* 64, 1259-1269.

- Nicolás, M., Noé, V., Jensen, K. B., and Ciudad, C. J. (2001). Cloning and characterization of the 5'-flanking region of the human transcription factor Sp1 gene. *J Biol Chem* 276, 22126-22132.
- Noti, J. D., Johnson, A. K., and Dillon, J. D. (2000). Structural and functional characterization of the leukocyte integrin gene CD11d. Essential role of Sp1 and Sp3. *J Biol Chem* 275, 8959-8969.
- Okamoto, Y., Sakata, M., Yamamoto, T., Nishio, Y., Adachi, K., Ogura, K., Yamaguchi, M., Takeda, T., Tasaka, K., and Murata, Y. (2001). Involvement of nuclear transcription factor Sp1 in regulating glucose transporter-1 gene expression during rat trophoblast differentiation. *Biochem Biophys Res Commun* 288, 940-948.
- Opitz, O. G., and Rustgi, A. K. (2000). Interaction between Sp1 and cell cycle regulatory proteins is important in transactivation of a differentiation-related gene. *Cancer Res* 60, 2825-2830.
- Parish, C. R. (1999). Fluorescent dyes for lymphocyte migration and proliferation studies. *Immunol Cell Biol* 77, 499-508.
- Peñuelas, S., Alemany, C., Noé, V., and Ciudad, C. J. (2003). The expression of retinoblastoma and Sp1 is increased by low concentrations of cyclin-dependent kinase inhibitors. *Eur J Biochem* 270, 4809-4822.
- Perego, P., Corna, E., Cesare, M. D., Gatti, L., Polizzi, D., Pratesi, G., Supino, R., and Zunino, F. (2001). Role of apoptosis and apoptosis-related genes in cellular response and antitumor efficacy of anthracyclines. *Curr Med Chem* 8, 31-37.
- Perez-Soler, R., Neamati, N., Zou, Y., Schneider, E., Doyle, L. A., Andreeff, M., Priebe, W., and Ling, Y. H. (1997). Annamycin circumvents resistance mediated by the multidrug resistance-associated protein (MRP) in breast MCF-7 and small-cell lung UMCC-1 cancer cell lines selected for resistance to etoposide. *Int J Cancer* 71, 35-41.
- Portugal, J., Martín, B., Vaquero, A., Ferrer, N., Villamarín, S., and Priebe, W. (2001). Analysis of the effects of daunorubicin and WP631 on transcription. *Curr Med Chem* 8, 1-8.
- Priebe, W., ed. (1995). *Antracycline Antibiotics: New Analogues, Methods of Delivery and Mechanisms of Action* (Washington, DC, American Chemical Society).
- Priebe, W., Fokt, I., Przewloka, T., Chaires, J. B., Portugal, J., and Trent, J. O. (2001). Exploiting anthracycline scaffold for designing DNA-targeting agents. *Methods Enzymol* 340, 529-555.
- Reisman, D., Elkind, N. B., Roy, B., Beamon, J., and Rotter, V. (1993). c-Myc transactivates the p53 promoter through a required downstream CACGTG motif. *Cell Growth Differ* 4, 57-65.
- Robinson, B. W., Ostruszka, L., Im, M. M., and Shewach, D. S. (2004). Promising combination therapies with gemcitabine. *Semin Oncol* 31, 2-12.

- Robinson, B. W., and Shewach, D. S. (2001). Radiosensitization by gemcitabine in p53 wild-type and mutant MCF-7 breast carcinoma cell lines. *Clin Cancer Res* 7, 2581-2589.
- Robinson, H., Priebe, W., Chaires, J. B., and Wang, A. H. J. (1997). Binding of two novel bisdaunorubicins to DNA studied by NMR spectroscopy. *Biochemistry* 36, 8663-8670.
- Robles, S. J., and Adami, G. R. (1998). Agents that cause DNA double strand breaks lead to p16<sup>INK4a</sup> enrichment and the premature senescence of normal fibroblasts. *Oncogene* 16, 1113-1123.
- Roninson, I. B. (2002). Tumor senescence as a determinant of drug response in vivo. *Drug Resist Updat* 5, 204-208.
- Roninson, I. B., Broude, E. V., and Chang, B. D. (2001). If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. *Drug Resist Updat* 4, 303-313.
- Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989). *Molecular Cloning. A laboratory manual*, 2nd edn (New York, Cold Spring Harbour Lab.).
- Schmitt, C. A., Fridman, J. S., Yang, M., Lee, S., Baranov, E., Hoffman, R. M., and Lowe, S. W. (2002). A senescence program controlled by p53 and p16<sup>INK4a</sup> contributes to the outcome of cancer therapy. *Cell* 109, 335-346.
- Schneider, E., Horton, J. K., Yang, C. H., Nakagawa, M., and Cowan, K. H. (1994). Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. *Cancer Res* 54, 152-158.
- Seluanov, A., Gorbunova, V., Falcovitz, A., Sigal, A., Milyavsky, M., Zurer, I., Shohat, G., Goldfinger, N., and Rotter, V. (2001). Change of the death pathway in senescent human fibroblasts in response to DNA damage is caused by an inability to stabilize p53. *Mol Cell Biol* 21, 1552-1564.
- Semenov, D. V., Aronov, P. A., Kuligina, E. V., Potapenko, M. O., and Richter, V. A. (2004). Oligonucleosome DNA fragmentation of caspase 3 deficient MCF-7 cells in palmitate-induced apoptosis. *Nucleosides Nucleotides Nucleic Acids* 23, 831-836.
- Shankar, S. L., Mani, S., O'Guin, K. N., Kandimalla, E. R., Agrawal, S., and Shafit-Zagardo, B. (2001). Survivin inhibition induces human neural tumor cell death through caspase-independent and -dependent pathways. *J Neurochem* 79, 426-436.
- Shay, J. W., and Roninson, I. B. (2004). Hallmarks of senescence in carcinogenesis and cancer therapy. *Oncogene* 23, 2919-2933.
- Shay, J. W., and Wright, W. E. (2004). Senescence and immortalization: role of telomeres and telomerase. *Carcinogenesis*.

- Sjøttem, E., Andersen, C., and Johansen, T. (1997). Structural and functional analyses of DNA bending induced by Sp1 family transcription factors. *J Mol Biol* 267, 490-504.
- Smits, V. A., and Medema, R. H. (2001). Checking out the G(2)/M transition. *Biochim Biophys Acta* 1519, 1-12.
- Soussi, T., and Beroud, C. (2001). Assessing TP53 status in human tumours to evaluate clinical outcome. *Nature Rev Cancer* 1, 233-240.
- Studzinski, G. P., Rathod, B., Rao, J., Kheir, A., Wajchman, H. J., Zhang, F., Finan, J. B., and Nowell, P. C. (1996). Transition to tetraploidy in 1,25-dihydroxyvitamin D3-resistant HL60 cells is preceded by reduced growth factor dependence and constitutive up-regulation of Sp1 and AP-1 transcription factors. *Cancer Res* 56, 5513-5521.
- Suske, G. (1999). The Sp-family of transcription factors. *Gene* 238, 291-300.
- te Poele, R. H., Okorokov, A. L., Jardine, L., Cummings, J., and Joel, S. P. (2002). DNA damage is able to induce senescence in tumor cells in vitro and in vivo. *Cancer Res* 62, 1876-1883.
- Thuong, N. T., and Hélène, C. (1993). Sequence-specific recognition and modification of double-strand by oligonucleotides. *Angew Chem (Int Ed)* 32, 666-690.
- Tsugu, A., Sakai, K., Dirks, P. B., Jung, S., Weksberg, R., Fei, Y. L., Mondal, S., Ivanchuk, S., Ackerley, C., Hamel, P. A., and Rutka, J. T. (2000). Expression of p57(KIP2) potently blocks the growth of human astrocytomas and induces cell senescence. *Am J Pathol* 157, 919-932.
- Tuck, S. P., and Crawford, L. (1989). Characterization of the human *p53* gene promoter. *Mol Cell Biol* 9, 2163-2172.
- Udvardia, A. J., Rogers, K. T., Higgins, P. D., Murata, Y., Martin, K. H., Humphrey, P. A., and Horowitz, J. M. (1993). Sp-1 binds promoter elements regulated by the RB protein and Sp-1-mediated transcription is stimulated by RB coexpression. *Proc Natl Acad Sci USA* 90, 3265-3269.
- Valentini, L., Nicoletta, V., Vannini, E., Menozzi, M., Penco, S., and Arcamone, F. (1985). Association of anthracycline derivatives with DNA: a fluorescence study. *Il Farmaco* 40, 377-390.
- Vaquero, A., and Portugal, J. (1998). Modulation of DNA-protein interactions in the P1 and P2 *c-myc* promoters by two intercalating drugs. *Eur J Biochem* 251, 435-442.
- Vermes, I., Haanen, C., Steffens-Nakken, H., and Reutelingsperger, C. (1995). A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. *J Immunol Methods* 184, 39-51.

- 
- Villamarín, S., Ferrer-Miralles, N., Mansilla, S., Priebe, W., and Portugal, J. (2002). Induction of G2/M arrest and inhibition of *c-myc* and *p53* transcription by WP631 in Jurkat T cells. *Biochem Pharmacol* 63, 1251-1258.
- Villamarín, S., Mansilla, S., Ferrer-Miralles, N., Priebe, W., and Portugal, J. (2003). A comparative analysis of the time-dependent antiproliferative effects of daunorubicin and WP631. *Eur J Biochem* 270, 764-770.
- Viñals, F., Fandos, C., Santalucia, T., Ferré, J., Testar, X., Palacín, M., and Zorzano, A. (1997). Myogenesis and MyoD down-regulate Sp1. A mechanism for the repression of GLUT1 during muscle cell differentiation. *J Biol Chem* 272, 12913-12921.
- Vogelstein, B., Lane, D., and Levine, A. J. (2000). Surfing the p53 network. *Nature* 408, 307-310.
- von Hippel, P. H., and Berg, O. G. (1986). On the specificity of DNA-protein interactions. *Proc Natl Acad Sci USA* 83, 1608-1612.
- Wang, X., Tsao, S. W., Wong, Y. C., and Cheung, A. L. (2003). Induction of senescent-like growth arrest as a new target in anticancer treatment. *Curr Cancer Drug Targets* 3, 153-159.
- Wei, W., and Sedivy, J. M. (1999). Differentiation between senescence (M1) and crisis (M2) in human fibroblast cultures. *Exp Cell Res* 253, 519-522.
- Weiss, R. B. (1992). The anthracyclines: will we ever find a better doxorubicin? *Semin Oncol* 19, 670-686.
- White, C. M., Satz, A. L., Gawron, L. S., Bruice, T. C., and Beerman, T. A. (2002). Inhibiting transcription factor/DNA complexes using fluorescent microgonotropens (FMGTs). *Biochim Biophys Acta* 1574, 100-108.
- White, E. (1996). Life, death, and the pursuit of apoptosis. *Genes Dev* 10, 1-15.
- Zhang, Y., and Berger, S. A. (2003). Ketotifen reverses MDR1-mediated multidrug resistance in human breast cancer cells in vitro and alleviates cardiotoxicity induced by doxorubicin in vivo. *Cancer Chemother Pharmacol* 51, 407-414.
- Zunino, F., and Capranico, G. (1990). DNA topoisomerase II as the primary target of anti-tumor anthracyclines. *Anticancer Drug Des* 5, 307-317.

